Caplin Point Laboratories Limited

Caplin Point Laboratories Ltd is a public listed company offering a wide range of pharmaceutical formulations with end to end operations in Latin America, South East Asia and Africa. Caplin holds over 1000 product registrations in 22 countries across the globe. In 2012, Caplin had taken a major step of entering into regulated markets by commencing construction of an integrated facility that would be in compliance with US FDA, ANVISA and UK MHRA norms for Liquid Injectables in Vials and Ampoules, Lyophilized products and Ophthalmic drugs. The plant is expected to be fully functional by early 2014.